# Trial to Compare the Efficacy and Safety of NNC0195-0092 (Somapacitan) With Placebo and Norditropin® FlexPro® (Somatropin) in Adults With Growth Hormone Deficiency.

> **NCT02229851** · PHASE3 · COMPLETED · sponsor: **Novo Nordisk A/S** · enrollment: 301 (actual)

## Conditions studied

- Growth Hormone Disorder
- Adult Growth Hormone Deficiency

## Interventions

- **DRUG:** somapacitan
- **DRUG:** somatropin
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT02229851
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-10-31
- **Primary completion:** 2017-04-21
- **Final completion:** 2018-05-07
- **Target enrollment:** 301 (ACTUAL)
- **Last updated:** 2020-11-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02229851

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02229851, "Trial to Compare the Efficacy and Safety of NNC0195-0092 (Somapacitan) With Placebo and Norditropin® FlexPro® (Somatropin) in Adults With Growth Hormone Deficiency.". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT02229851. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*